AstraZeneca Sues FDA On Crestor Generics: Fighting A 'Foregone Conclusion'?
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
You may also be interested in...
FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule
Agency rejects PhRMA requests to ease certification process and limit rule's application; separately, law firm Hyman, Phelps & McNamara objects to FDA practice of delaying ANDA approval announcements until it issues a petition decision.
Crestor Generics To Launch After 12-Day Delay
AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.
Crestor Generics On Hold As FDA, AstraZeneca Talk About Exclusivity
Court postpones a decision on a temporary restraining order and asks parties to reach agreement on how FDA is to proceed with pending ANDAs.